Influence of HLA-class II incompatibility between mother and fetus on the development and course of rheumatoid arthritis of the mother

I E van der Horst-Bruinsma, R R P de Vries, P D M de Buck, P W van Schendel, F C Breedveld, G M Th Schreuder, J M W Hazes

Abstract

Objective—To assess the relation between the course of rheumatoid arthritis (RA) during pregnancy or the onset of RA postpartum and DRB1, DQA1, and DQB1 incompatibilities between mother and child.

Methods—In 45 pregnancies of 33 RA patients the course of RA was related to the number of class II incompatibilities. Furthermore class II incompatibilities in 16 pregnancies followed by RA onset were compared with those in 87 control pregnancies.

Results—The risk of a favourable compared with an unfavourable course was 0.95, 2.67, and 2.38 in case of DRB1, DQA1, and DQB1 incompatibility respectively. DQA1 and DQB1 incompatibilities were seen more often in the 10 pregnancies followed by RA onset within three months than in control pregnancies (OR 8.02, 95% CI 0.97, 66.06 and OR 8.79 95% CI 1.07, 72.46 respectively).

Conclusions—DQA1 and DQB1 incompatibility between mother and child seems to have a favourable effect on the course of RA and may postpone the risk of RA onset during pregnancy.

(Please note: the abstract is not translated into the appropriate language as per the instruction.)

Pregnancy may, apart from influencing the course of RA, also play a part in the onset of RA. The risk of RA onset within three months post partum (OR 3.37–5.6) is increased and remains higher during the first year post partum (OR 2.6).** The risk of developing RA during pregnancy was found to be decreased (OR 0.30 and OR 0.63). The increased risk of RA onset in the postpartum period may also be explained in two ways: by hormonal mechanisms and by incompatibility in HLA class II antigens between mother and child. In both alternatives the disease onset is postponed because of the suppressive effect of pregnancy.

This study aimed to investigate (1) whether incompatibility in DRB1, DQA1, and DQB1 between mother and child is associated with a decrease in disease activity of RA during pregnancy and (2) whether HLA class II incompatibilities are associated with the risk of RA onset post partum in the mother. In addition the influence of the sex of the child on the onset and course of RA was studied.

Methods

Patients

Women visiting the outpatient clinic of the Rheumatology Department of the University Hospital Leiden from February 1994 until March 1995 and who developed RA during their childbearing years were asked to participate in the study. The included patients fulfilled the 1987 ACR criteria for RA.** Information about their pregnancies, miscarriages, the disease activity, and the medication used in the periods before, during, and after the pregnancies was obtained by patient interviews and by reviewing the medical records. Pregnancies with a RA onset within one year after delivery were considered as “onset related pregnancies” (n=16). Pregnancies after the onset of RA were considered as “course pregnancies” (n=33). The pregnancies of RA women who did not yet suffer from RA at that time nor had an RA onset within one year post partum were considered as “RA control pregnancies” (n=16). The 71 “non-RA control pregnancies” were recruited from a study where the pregnancies of non-RA mothers of RA children were studied in the scope of the Non Inherited Maternal Antigen (NIMA) hypothesis that influences the risk of RA.** Differences in HLA-DR and DQ antigens between mother and child for each pregnancy were related to the onset and course of RA in the mother. The study was designed as a case-
control study in which the incompatibility of HLA-DR and DQ antigens between mother and child is the exposure variable. The time of onset of RA and the disease course during pregnancy are the outcome variables. The “cases” included either pregnancies related to the onset of RA (as “controls”) pregnancies without an RA onset post partum were studied) or pregnancies during which the course of RA was studied (cases with a favourable course compared with cases with an unfavourable course). This implicates that one woman may contribute none or one “onset related pregnancy” and none or several “course pregnancies” depending on the onset of RA during her childbearing period.

To compare the number of incompatibilities in pregnancies followed by the onset of RA, the pregnancies of 87 women who did not develop RA at all were added to see whether this would show another pattern of incompatibilities in this larger group.

The study was approved by the medical ethical committee and informed consent was obtained from all subjects or from their parents.

COURSE OF RA DURING PREGNANCY
The course of RA during pregnancy was considered either favourable, unfavourable or unchanged. The incompatibility of HLA-DR and DQ in pregnancies with a favourable course were compared with those found in pregnancies with an unfavourable course. As this was a retrospective study, the information about the course of the disease during pregnancy was obtained from the medical charts and by a structural interview of the patients. The assessment of disease activity before, during, and after pregnancy is therefore not objective. It is known, however, that patients and doctors assessments are very sensitive and relevant instruments to measure disease activity and were therefore thought to be the most reasonable measurements to use in this study. The doctor’s assessment of disease activity and the medication used three months before, during pregnancy, and in the year post partum were obtained by reviewing the medical record. The patient’s assessment was obtained by an interview in which the patient could choose between remission, exacerbation or unchanged activity of RA in the before, during or after pregnancy periods. A favourable course was defined as decreased disease activity or remission of RA compared with the period before the pregnancy. In that case at least two of the following criteria had to be present: (1) remission or amelioration of disease during pregnancy according to the doctor’s assessment, (2) same as in (1) but according to the patient’s assessment, and (3) no increase of disease activity after the medication for RA had been stopped in the first trimester of the pregnancy.

An unfavourable course was defined as persistent disease activity or a flare of the disease during pregnancy. In that case at least two of the following criteria had to be present: (1) active disease during pregnancy according to the doctor’s assessment, (2) same as in (1) but according to the patient’s assessment, and (3) continuation of medication despite pregnancy. Cases with low disease activity before, during, and after the pregnancy were not included in this study, because the advantageous influence of the pregnancy on the course of RA could not be evaluated.

ONSET OF RA
The onset of RA was defined as the first symptoms of arthritis that finally resulted in the diagnosis of RA according to the ACR criteria.

The DR and DQ incompatibilities of pregnancies followed by a RA onset within one year (“onset related pregnancies”) were compared with (1) RA and non-RA control pregnancies, (2) pregnancies within the same women as the onset related pregnancies, but before the RA developed. Because the risk of RA onset is the highest within three months post partum a separate analysis was performed on pregnancies followed by RA onset within this period.

HLA TYPING
DNA was isolated from blood lymphocytes of the mothers and of the children included in the study. Generic DRB typing was performed with a polymerase chain reaction and biotin labelled sequence specific oligonucleotide (PCR-SSO) method as described previously. This method allows medium resolution specific amplification of DNA from all DRB1*04 positive women and hybridisation with relevant SSOS. In this way it was possible to distinguish homozygosity and heterozygosity for all DRB1*04 alleles and for the alleles known to express the shared epitope—that is, DRB1*0101, *0102, *0401, *0405, *0408, *0410, *1001, *1402, *1406. Generic DQA1 (0101–0104, 0201, 03, 0401, 0501, 0502 and 0601) and DQB1 (0501–0504, 0601–0609, 0201, 0202, 0301–0305, 0401, 0402) typing was performed with a PCR-SSO method as described previously.

HLA class II incompatibilities between mother and child were defined from the perspective of the mother. Incompatibility was considered to be present if a HLA allele of the child differed from both maternal alleles.

STATISTICS
The differences in the number of incompatibilities in DRB1, DQA1, and DQB1 between the onset pregnancies, course pregnancies, and control pregnancies were tested with the $\chi^2$ test. The association between incompatibility and either favourable course of RA during pregnancy, or onset of RA post partum were represented as odds ratios with 95% confidence intervals. When the figure zero came up in the $\chi^2$ test a calculation was made adding 0.5 to all cells.

The comparison of incompatibilities in pregnancies within one woman was made considering the “onset related pregnancy” as reference case and the pregnancies before the onset...
Table 1  Course(*) of RA during pregnancy in relation to incompatibility of DRB1, DQA1, and DQB1 between mother and child

<table>
<thead>
<tr>
<th>Incompatibility†</th>
<th>Favourable (n=21-23)</th>
<th>Unfavourable (n=5-6)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB1 +</td>
<td>19</td>
<td>5</td>
<td>0.95 (0.09, 10.5)</td>
</tr>
<tr>
<td>DRB1 −</td>
<td>4</td>
<td>1</td>
<td>2.67 (0.42, 17.05)</td>
</tr>
<tr>
<td>DQA1 +</td>
<td>16</td>
<td>3</td>
<td>3.86 (0.03, 14.52)</td>
</tr>
<tr>
<td>DQA1 −</td>
<td>6</td>
<td>3</td>
<td>2.38 (0.17, 33.00)</td>
</tr>
<tr>
<td>DQB1 +</td>
<td>19</td>
<td>4</td>
<td>2.38 (0.17, 33.00)</td>
</tr>
<tr>
<td>DQB1 −</td>
<td>2</td>
<td>1</td>
<td>2.38 (0.17, 33.00)</td>
</tr>
</tbody>
</table>

*Course: disease activity of RA during pregnancy. Favourable: remission or amelioration of disease during pregnancy according to the criteria described in the methods. Unfavourable: active disease during pregnancy according to the criteria described in the methods. In 12 pregnancies the course of RA did not change and among these were 11 DRB1, 10 DQA1, and 7 DQB1 incompatibilities; they were not included in the calculations. †Incompatibility: when a child has an allele that is different from both maternal alleles. In some cases it was not possible to differentiate between incompatibility and compatibility according to the HLA data and they were left out, so the number of pregnancies vary for the different class II subtypes.

Results

Of the 362 patients interviewed 62 women were eligible for the study and agreed to participate. These 62 women gave birth to 160 children of which 142 children participated in the study. The women had a mean number of children of 2.6 and a mean age of RA onset of 33 years. Forty five (72%) RA patients were rheumatoid factor positive, 44 (71%) had arthritic erosions, and 11 (18%) nodules. Alleles expressing the shared epitope were found in a double dose in 13 women (21%), a single dose in 37 women (60%), and none in 14 women (22%).

Course of RA

The course of RA could be studied in only 45 pregnancies of 20 women, because the other women have not yet developed RA in their childbearing period. The pregnancies of these women served as controls. Twelve pregnancies were excluded because of low disease activity before the pregnancy and no change of RA during or after the pregnancy. None of the women showed a favourable course during one pregnancy and an unfavourable course in the other pregnancy. A combination of an unchanged low level of disease activity in one pregnancy as control pregnancies. All the pregnancies of one woman were considered as a matched set. The incompatibility was the exposure.

Onset of RA

Sixteen women developed RA within one year after delivery. The HLA incompatibilities of these pregnancies were compared with the HLA incompatibilities of the RA and non-RA control pregnancies. It was not possible to differentiate between incompatibility and compatibility according to the HLA data in eight pregnancies in DRB1, seven DQA1, and in nine DQB1 typings, all from the control group. RA onset post partum was slightly increased in case of DRB1 incompatibility (OR 1.37, 95% CI 0.41, 4.65), but more in case of DQA1 (OR 3.86, 95% CI 1.03, 14.52) and DQB1 incompatibility (OR 4.23, 95% CI 1.12, 15.9).

By restricting the analysis to the 10 women who experienced RA onset within three months post partum, the risk for DRB1 incompatibility remained similar (OR 1.83 95% CI 0.36, 9.20) but increased to 8.02 (95% CI 0.97, 66.06) and 8.79 (95% CI 1.07, 72.46) in case of DQA1 and DQB1 incompatibility respectively (table 2). If RA control and non-RA control pregnancies were considered separately, similar results were obtained. In the matched analysis all pregnancies within one woman were considered as a matched set. The conditional logistic regression analysis using the statistical program Egret did not result in a defined odds ratio, because of the small numbers. Therefore the crude data are also presented (table 3).

When RA onset related pregnancies are restricted to the ones followed by RA within three months post partum all six pregnancies show incompatibility in DQA1, DQB1, and DRB1. Also every pregnancy before these “RA onset related pregnancies within three months” show incompatibilities of these three class II types except for one case of DQB1 compatibility.

In case of a male child the risk of developing RA post partum was (not significantly) higher than in case of a female child (OR 1.85, 95% CI 0.48, 7.18). The risk of an unfavourable course of RA during pregnancy was (not significantly) increased by a male child compared with a female child (OR 1.6, 95% CI 0.25, 10.2).
**Discussion**

DQA1 and DQB1 incompatibility between mother and child was found more often in pregnancies with a favourable course of RA than in those with an unfavourable course. There was no relation between DRB1 incompatibilities and the course of RA. In addition pregnancies with a postpartum onset of RA within three months also showed an increased number of DQ incompatibilities and no effect of DRB1 incompatibilities when compared with pregnancies of women who did not develop RA in their childbearing years.

Despite a major effort to include as many women as possible, the number of women that could be studied remained low as in most women RA started several years after child birth.

**COURSE OF RA DURING PREGNANCY**

Many theories have been proposed to explain why RA ameliorates during pregnancy and often exacerbates post partum. Hormones like oestrogen, progesterone, corticosteroid, and prolactin have been put forward. Also it has been postulated that androgens have an anti-inflammatory effect on RA and according to some even the small amounts produced by a male fetus might ameliorate RA during pregnancy. An explanation of the ameliorating effect of pregnancy in RA by androgen concentrations as result of sex differences of the children could not be confirmed in this study.

The hormonal theories cannot explain, however, why the course of RA may vary during different pregnancies. The fact that every pregnancy results in a different set of class II incompatibilities that has a different effect on disease activity of RA may offer an attractive explanation. Leucocytes or shed soluble HLA molecules of the child may enter the maternal circulation and influence the maternal immune response in a still undefined way. This is illustrated by the lymphocytotoxic anti-HLA ABC and DR antibodies found in 9% of the women after their first and 18% after subsequent pregnancies.

This study shows a clear trend towards a disease suppressing effect of DQA1 and DQB1 incompatibility during pregnancy, confirming the study of Nelson. In line with this previous study there seems to be a greater influence of DQ than of DR (mis)matching on the course of RA. The immunogenetic methods of both studies were compared in detail and showed no differences in DNA typing techniques nor in interpretation of incompatibility. Compared with Nelson et al we observed more often a favourable course, which fits with the fact that we observed more often DR and DQ incompatibilities. The present data support the notion that DQ molecules may be involved in the predisposition to and course of RA. The influence of DQ (in particular DQ7) on disease severity of RA has been shown in a study comparing mild with severe forms of RA in DR4 positive RA patients. Based on evidence in transgenic mouse models Zanelli suggested that DQ rather than DR alleles predispose to RA.

**ONSET OF RA IN RELATION TO PREGNANCY**

The onset of RA in women during their fertile lifetime was found to be related in 23–30% of the women to a pregnancy. In 15% of the women the disease develops within three months post partum and in 5% between three months and one year post partum.

There is much debate about the mechanism that explains the increased risk of RA onset within three months post partum. One explanation is that hormonal or immunological mechanisms may play a part in postponing the onset of RA by suppressing disease activity during pregnancy. The relatively low incidence of RA onset during pregnancy supports this theory. In accordance with pregnancies associated with a favourable course, pregnancies followed by RA onset also showed an increased number of DQA and DQB incompatibilities compared with controls. Therefore we interpret this as being the result of an extra suppressive effect during pregnancy of an ongoing RA that became manifest within three months post partum. The results of the matched analysis that showed that the majority of the women with a RA onset within three months post partum already had been exposed to an incompatibility before, can be explained by the absence of other susceptibility factors during the previous pregnancies. However, the numbers in that analysis were too small to challenge this hypothesis or to deserve an additional explanation.

To our knowledge the topic of HLA incompatibility, inclusive DQA1 and DQB1, between mother and child and the onset of RA has not been studied before. Brennan et al found no association between fatally inherited DRB1 paternal antigens and the onset of RA within the mother, but these investigators did not look into HLA incompatibilities between mother and child.

---

**Table 3** HLA incompatibility of the RA onset related pregnancy and the previous pregnancies of these women

<table>
<thead>
<tr>
<th>Woman</th>
<th>Pregnancies</th>
<th>DQA1</th>
<th>DQB1</th>
<th>DRB1</th>
<th>RA onset post partum</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>yes</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>yes</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>yes</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>yes</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>yes</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>yes</td>
</tr>
</tbody>
</table>

0 = Compatibility, 1 = incompatibility.

---
and child by comparing each pregnancy of a woman.

In conclusion, QB1 and DQA1 incompatibilities between mother and child were found more often in pregnancies with a favourable course compared with those with an unfavourable course. Also DQA1 and DQB1 incompatibilities were seen more often in pregnancies followed by RA onset than among control pregnancies, which suggests that DQ incompatibility might postpone the onset of RA. These results support the suggestion put forward by others that DQ antigens may play a more prominent part in RA than has been generally appreciated until now.

Influence of HLA-class II incompatibility between mother and fetus on the development and course of rheumatoid arthritis of the mother

I E van der Horst-Bruinsma, R R P de Vries, P D M de Buck, P W van Schendel, F C Breedveld, G M Th Schreuder and J M W Hazes

doi: 10.1136/ard.57.5.286

Updated information and services can be found at:
http://ard.bmj.com/content/57/5/286

**References**

This article cites 31 articles, 6 of which you can access for free at:
http://ard.bmj.com/content/57/5/286#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/